MMP9 and arthritic joint disease: Similarly, pharmacological inhibition of the LPA1 receptor by Ki16425 in the K/BxN serum-transfer arthritis model led to a reduction in arthritis severity by decreasing cartilage damage, bone erosion, and expression of RANKL, ITAC/CXCL11, Pro-MMP9, and MMP3, in mouse arthritic joints [69].